MSB 7.69% $1.19 mesoblast limited

Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease, page-134

  1. 7,151 Posts.
    lightbulb Created with Sketch. 45
    Re "I wonder where @madamswer, @aatisket, @Fruitbat2 and others are?"
    I spent the past day in the garden. It has been a belter of a day in Melbourne, thanks for your concern.

    I was just thinking it must soon be 10 years since you first predicted one of MSB's products will be fast tracked for some long since forgotten medical matter and, with that, perhaps 9 years and 364 days since you first suggested you deserved credit for your perceptive insight. 10 years of predicting something will happen quickly and yet it never quite made it. No matter, ever onwards, maybe the next decade will deliver the goods in the fast tracking arena, although, at some point, it will surely no longer be "fast" but instead more "normal to slow" tracking.

    I must admit, I've rather tuned out of MSB, there have been too many confusing messages for me. I'm sure you're still seeing the bright side and diligently guarding the investments of all of the mums and dads who have been hanging on your every word for all of this past decade.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.